ライフサイエンスコーパス: hyaluronate

1 orway rats by subretinal injection of sodium hyaluronate.

2 mice by subretinal injection of 1.4% sodium hyaluronate.

3 proximately half of the versican is bound to hyaluronate.

4 orm is independent of its ability to bind to hyaluronate.

5 oxygenated warm acellular buffer containing hyaluronate.

6 r the extracellular matrix glycosaminoglycan hyaluronate.

7 onstruct encoded a protein unable to bind to hyaluronate.

8 id not affect CD44-mediated cell adhesion to hyaluronate.

9 gnificantly modulates its ability to bind to hyaluronate.

10 ion proteins also enhanced their adhesion to hyaluronate.

11 tion between CD44 and a carbohydrate ligand, hyaluronate.

12 atly enhanced CD44-mediated cell adhesion to hyaluronate.

13 In order to study cell binding to hyaluronate, a novel assay was developed with hyaluronat

14 ratan sulfate modification of CD44 modulates hyaluronate adhesion through its B loop domain.

15 the US Food and Drug Administration: sodium hyaluronate and poly(vinylpyrrolidone).

16 cells roll under physiologic shear forces on hyaluronate and require VCAM-1, but not ICAM-1, as ligan

17 ild-type standard CD44 isoform increased the hyaluronate binding of prostate cancer cells and suppres

18 r level of standard CD44 isoform expression, hyaluronate binding, tumorigenicity, and metastatic abil

19 te cancer cells critically requires enhanced hyaluronate binding.

20 osaminoglycan side chain attachment, impairs hyaluronate binding.

21 ibited by an anti-CD44 antibody that blocked hyaluronate binding.

22 e recognition domain of CD44 is critical for hyaluronate binding.

23 utant CD44 standard isoform did not increase hyaluronate binding; however, it equally suppressed the

24 Use of plates coated with hyaluronate by this new method provides an ideal in vitr

25 Adhesion to hyaluronate by tumor cells has been shown to correlate w

26 ly lead to phagocytic ingestion and that the hyaluronate capsule and M proteins are variably importan

27 of M protein-fibrinogen interaction and the hyaluronate capsule in preventing phagocytic ingestion a

28 Sodium hyaluronate-carboxymethylcellulose (HA/CMC) formulations

29 stration-approved antiadhesion agent, sodium hyaluronate/carboxymethylcellulose (Seprafilm) by intrap

30 Seprafilm, a sodium hyaluronate/carboxymethylcellulose absorbable barrier de

31 Dispersion of ABM/P-15 in sodium hyaluronate carrier (PPutty) improves the handling prope

32 te demineralized bone matrices in a 2% or 4% hyaluronate carrier, respectively.

33 6 ml/g/min), increased resistance, decreased hyaluronate clearance (17 vs. 35 microg/g liver) and low

34 Bile output, alanine transferase, and hyaluronate clearance were measured during reperfusion.

35 reservation, flow (2.0 vs. 2.0), resistance, hyaluronate clearance, and bile output were similar in b

36 in the loss of attachment of these cells to hyaluronate-coated substrate.

37 es CD44-mediated melanoma cell attachment to hyaluronate-coated surfaces, suggesting that all five si

38 yaluronate, a novel assay was developed with hyaluronate covalently tethered to polystyrene plates in

39 ove chondroitin sulfate, heparan sulfate, or hyaluronate did not affect CD44-mediated cell adhesion t

40 ix; i.e. similar to that observed for sodium hyaluronate fibers by X-ray diffraction, but with the ac

41 vation of T cells increases their binding to hyaluronate (HA) and enables CD44-mediated primary adhes

42 ver, the levels of synovium-derived markers, hyaluronate (HA) and N-propeptide of type III procollage

43 be specifically achieved using both soluble hyaluronate (HA) and treatment of the adherent cells wit

44 s been characterized in depth, regulation of hyaluronate (HA) on endothelial cells has not been exten

45 een "activated" to bind its principal ligand hyaluronate (HA) on endothelium can mediate the primary

46 Synovial fluid is a semidilute hyaluronate (HA) polymer solution, the rheology of which

47 s interactions between T lymphocyte CD44 and hyaluronate (HA), a heteropolysaccharide that is express

48 inistration of the principal ligand of CD44, hyaluronate (HA), in soluble form, can inhibit CD44-HA i

49 etention at the cell surface is dependent on hyaluronate (HA).

50 as induced by subretinal injection of sodium hyaluronate in adult wild-type (WT) and GFAP-/-Vim-/- mi

51 anesthetized cats by injecting 0.25% sodium hyaluronate in balanced salt solution into the subretina

52 k pain-relieving effect, and intra-articular hyaluronate injections may also have a limited role.

53 lation and Ser-Gly motifs in regulating CD44-hyaluronate interaction.

54 CD44-mediated cell adhesion to hyaluronate is controlled by mechanisms which are poorly

55 Low molecular weight hyaluronate (LMW-HA) blocks interactions between T lymph

56 by the bacterial gene encoded extracellular hyaluronate lyase (HL), which degrades hyaluronan (HA),

57 The hyaluronate lyase (Hyl) presented on the surface of S. p

58 As pneumococci express a hyaluronate lyase (Hyl) that cleaves hyaluronic acid int

59 Streptococcus pneumoniae hyaluronate lyase (spnHL) is a pathogenic bacterial spre

60 Streptococcus agalactiae hyaluronate lyase degrades primarily hyaluronan, the mai

61 Hyaluronate lyase enzymes degrade hyaluronan, the main p

62 rystal structure of Streptococcus pneumoniae hyaluronate lyase in the presence of HA disaccharide pro

63 Streptococcus pneumoniae hyaluronate lyase is a surface antigen of this Gram-posi

64 Streptococcus pneumoniae hyaluronate lyase is a surface enzyme of this Gram-posit

65 Streptococcus agalactiae hyaluronate lyase is a virulence factor that helps this

66 yase, an enzyme which depolymerizes HA, thus hyaluronate lyase might contribute directly to bacterial

67 glycerol lipases PPA2105 and PPA1796 and the hyaluronate lyase PPA380 compared to that in untreated b

68 action between the Streptococcus peneumoniae hyaluronate lyase protein and the product, and supports

69 ased on the native Streptococcus peneumoniae hyaluronate lyase structure.

70 de hyaluronan complex with the S. agalactiae hyaluronate lyase was determined at 2.2 A resolution; th

71 ystal structures of Streptococcus pneumoniae hyaluronate lyase with tetra- and hexasaccharide hyaluro

72 Pneumococci and other streptococci produce hyaluronate lyase, an enzyme which depolymerizes HA, thu

73 bsequently observed in copper amine oxidase, hyaluronate lyase, chondroitinase, and maltose phosphory

74 onan degradation by Streptococcus pneumoniae hyaluronate lyase.

75 design of a stronger inhibitor of bacterial hyaluronate lyase.

76 ly to have an inhibitory effect on bacterial hyaluronate lyase.

77 llographic evidence for the binding of HA to hyaluronate lyase.

78 Evolutionary studies suggest that hyaluronate lyases evolved from chondroitin lyases and s

79 s of the S. agalactiae and the S. pneumoniae hyaluronate lyases.

80 se activity; however, all III-2 strains lack hyaluronate lysase activity, because the gene that encod

81 s, all RDP III-3 and III-1 strains expressed hyaluronate lysase activity; however, all III-2 strains

82 sase activity, because the gene that encodes hyaluronate lysase, hylB, is inactivated by IS1548.

83 after CD44 ligation by either osteopontin or hyaluronate may account for the independent effects of C

84 cific and cannot be duplicated by the use of hyaluronate or bovine serum albumin solutions.

85 Moreover, CD44H on KM12L4 bound to hyaluronate poorly compared to CD44H on KM12C6.

86 performed with lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1) and podoplanin antibodie

87 ning showed significant up-regulation of the hyaluronate receptor CD44 and stem cell factor receptor

88 icles bound to and inhibited DCs through the hyaluronate receptor CD44.

89 rkers LYVE-1 (lymphatic vascular endothelium hyaluronate receptor) and podoplanin contribute to lymph

90 st c-Kit, CD34 (binds L-selectin), and CD44 (hyaluronate receptor) receptors for biotinylated SCF res

91 CD44, a polymorphic hyaluronate receptor, may participate in chronic inflamm

92 tial N-linked glycosylation sites within the hyaluronate recognition domain of CD44 is critical for h

93 indicate that CD44 and its principal ligand hyaluronate represent another receptor/carbohydrate liga

94 try of blood into the cochlea and the use of hyaluronate seem to be reasonably supported, whereas the

95 o evaluate outcomes from the use of a sodium hyaluronate (SH)-based comfort drop, instilled before th

96 or an increase in CD44-mediated adhesion to hyaluronate, suggesting that complex N-linked oligosacch

97 tive at photolabeling Streptococcus pyogenes hyaluronate synthase in membrane preparations.

98 s inserted into the hasA gene, which encodes hyaluronate synthase, we found that all bacteria recover

99 ther 20 mg/ml of IL-1ra mixed in 0.2% sodium hyaluronate vehicle (n=28) or placebo alone (n=25).

100 CD44, the cell surface receptor for hyaluronate, was overexpressed in COX-2-S cells, and spe